Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys

Journal of Pharmacological and Toxicological Methods

Volumn 63, Issue 3, 2011, Pages 304-313

  Watson, Kenny J ^a   Gorczyca, William P ^b   Umland, John ^b   Zhang, Ying ^b   Chen, Xian ^b   Sun, Sunny Z ^b   Fermini, Bernard ^b   Holbrook, Mark ^a   Van Der Graaf Piet H , P H ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Cynomolgus monkey; Dofetilide; Moxifloxacin; PKPD; QT interval; QTc

Indexed keywords

DOFETILIDE; MOXIFLOXACIN; PLASMA PROTEIN; POTASSIUM CHANNEL HERG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXPOSURE; DRUG PROTEIN BINDING; EXPERIMENTAL MONKEY; HEMODYNAMIC MONITORING; IN VIVO STUDY; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; QT PROLONGATION; QUANTITATIVE ANALYSIS;

ACTION POTENTIALS; ADMINISTRATION, ORAL; ANIMALS; AZA COMPOUNDS; BLOOD PROTEINS; CELL LINE; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; MACACA FASCICULARIS; PATCH-CLAMP TECHNIQUES; PROTEIN BINDING; QUINOLINES; TELEMETRY; TRANSFECTION;

ANIMALIA; MACACA FASCICULARIS;

EID: 79954619247     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.03.002     Document Type: Article

References (40)

1. Alexandrou A.J., Duncan R.S., Sullivan A., Hancox J.C., Leishman D.J., Witchel H.J., Leaney J.L. Mechanism of hERG channel blockade by the fluroquinolone antibiotic Moxifloxacin. British Journal of Pharmacology 2006, 147:905-915.
2. Authier S., Pugsley M.K., Troncy E., Curtis M.J. Arrhythmogenic liability screening in cardiovascular safety pharmacology: Commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies. Journal of Pharmacological and Toxicological Methods 2010, 62:83-88.
3. Balfour J.A., Wiseman L.R. Moxifloxacin. Drugs 1999, 57:363-373.
4. Bazett H. An analysis of the time-relations of electrocardiograms. Heart 1920, 7:353-370.
5. Bischoff U., Schmidt C., Netzer R., Pongs O. Effects of fluoroquinolones on HERG currents. European Journal of Pharmacology 2000, 406:341-343.
6. c and implications for the design of thorough QT studies. Clinical Pharmacology and Therapeutics 2008, 84:475-480.
7. Brown A.M. Drugs, hERG and sudden death. Cell Calcium 2004, 35:543-547.
8. Cavero I., Crumb W. Moving towards better predictors of drug-induced Torsade de Pointes. 2-3 November 2005, Crystal City, Virginia, USA. Expert Opinion on Drug Safety 2006, 5:335-340.
9. Chaves A.A., Keller W.J., O'Sullivan S., Williams M.A., Fitzgerald L.E., McPherson H.E., Goykhman D., Ward P.D., Hoe C.M., Mixson L., Briscoe R.J. Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. Journal of Pharmacological and Toxicological Methods 2006, 54:150-158.
10. Cordes J.S., Sun Z., Lloyd D.B., Bradley J.A., Opsahl A.C., Tengowski M.W., Chen X., Zhou J. Pentamidine reduces hERG expression to prolong the QT interval. British Journal of Pharmacology 2005, 145:15-23.
11. Culley C.M., Lacy M.K., Klutman N., Edwards B. Moxifloxacin: Clinical efficacy and safety. American Journal of Health Syststem Pharmacy 2001, 58:379-388.
12. c prolongation and proarrhythmic potential for nonantiarrhythmic drugs: The international conference on harmonization of technical requirements for registration of pharmaceuticals for human use E14 guideline. Journal of Clinical Pharmacology 2006, 46:498-507.
13. De Ponti F., Poluzzi E., Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: A call for consensus. European Journal of Clinical Pharmacology 2001, 57:185-209.
14. c study in healthy subjects. British Journal of Clinical Pharmacology 2008, 66:396-404.
15. Fermini B., Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews. Drug Discovery 2003, 2:439-447.
16. Finlayson K., Witchel H.J., McCulloch J., Sharkey J. Acquired QT interval prolongation and HERG: Implications for drug discovery and development. European Journal of Pharmacology 2004, 500:129-142.
17. Fridericia L. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Medica Scandinavica 1920, 53:469-486.
18. Gabrielsson J., Green A.R., van der Graaf P.H. Optimising in vivo pharmacology studies - Practical PKPD considerations. Journal of Pharmacological and Toxicological Methods 2010, 61:146-156.
19. Garnett C.E., Beasley N., Bhattaram V.A., Jadhav P.R., Madabushi R., Stockbridge N., Tornoe C.W., Wang Y., Zhu H., Gobburu J.V. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. Journal of Clinical Pharmacology 2008, 48:13-18.
20. Giorgi Mariano A., Bolanos R., Gonzalez Claudio D., Di Girolamo G. QT interval prolongation: Preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Current Drug Safety 2010, 5:54-57.
21. Holzgrefe H.H., Cavero I., Buchanan L.V., Gill M.W., Durham S.K. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: Effects of Moxifloxacin. Journal of Pharmacological and Toxicological Methods 2007, 55:227-237.
22. Hulhoven R., Rosillon D., Letiexhe M., Meeus M.A., Daoust A., Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: Results from a thorough QT study. European Journal of Clinical Pharmacology 2007, 63:1011-1017.
23. Hutmacher M.M., Chapel S., Agin M.A., Fleishaker J.C., Lalonde R.L. Performance characteristics for some typical QT study designs under the ICH E-14 guidance. Journal of Clinical Pharmacology 2008, 48:215-224.
24. Jonker D.M., Kenna L.A., Leishman D., Wallis R., Milligan P.A., Jonsson E.N. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of Dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clinical Pharmacology and Therapeutics 2005, 77:572-582.
25. + channel HERG. Molecular Pharmacology 2001, 59:122-126.
26. Kao L.W., Furbee R.B. Drug-induced Q-T prolongation. The Medical Clinics of North America 2005, 89:1125-1144.
27. Komatsu R., Honda M., Holzgrefe H.H., Kubo J., Yamada Y., Isobe T., Kimura K., Itoh T., Tamaoki N., Tabo M. Sensitivity of common marmosets to detect drug-induced QT interval prolongation: Moxifloxacin case study. Journal of Pharmacological and Toxicological Methods 2010, 61:271-276.
28. Le Coz F., Funck-Brentano C., Morell T., Ghadanfar M.M., Jaillon P. Pharmacokinetic and pharmacodynamic modelling of the effects of Dofetlide on ventricular repolarization. Clinical Pharmacology and Therapeutics 1995, 57:533-542.
29. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. Journal of Cardiovascular Electrophysiology 2001, 12:411-420.
30. c prolongation. Pacing and Clin Electrophysiology 2004, 27:791-800.
31. c changes due to Moxifloxacin infusion. Journal of Clinical Pharmacology 2009, 49:674-683.
32. Nolan E.R., Feng R.F., Koup J.R., Liu J., Turluck D., Zhang Y., Paulissen J.B., Olivier N.B., Miller T., Bailie M.B. A novel predictive pharmacokinetic/pharmacodynamic model of the repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic av node-ablated, His bundle-paced dog. Journal of Pharmacological and Toxicological Methods 2005, 53:1-10.
33. Ollerstam A., Visser S.A., Duker G., Forsberg T., Persson A.H., Nilsson L.B., Bjorkman J.A., Gabrielsson J., Al-Saffar A. Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. Journal of Pharmacological and Toxicological Methods 2007, 56:131-144.
34. Ollerstam A., Visser S.A., Persson A.H., Eklund G., Nilsson L.B., Forsberg T., Wilklund S.J., Gabrielsson J., Duker G., Al-Saffar A. Pharmacokinetic-pharmacodynamic modelling of drug-induced effect on the QT interval in conscious telemetered dogs. Journal of Pharmacological and Toxicological Methods 2005, 53:174-183.
35. Peters R.W., Byington R.P., Barker A., Yusuf S. Prognostic value of prolonged ventricular repolarization following myocardial infarction: the BHAT experience. The BHAT Study Group. Journal of Clinical Epidemiology 1990, 43:167-172.
36. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58:32-45.
37. Schoemaker R.C., Cohen A.F. Estimating impossible curves using NONMEM. British Journal of Clinical Pharmacology 1996, 42:283-290.
38. Shah R.R. The significance of QT interval in drug development. British Journal of Clinical Pharmacology 2002, 54:188-202.
39. Volberg W.A., Koci B.J., Su W., Lin J., Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. The Journal of Pharmacology and Experimental Therapeutics 2002, 302(302):320-327.
40. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., January C.T. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophysical Journal 1998, 74:230-241.